We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.28B 31.19%
47,269,424
– –
ONC
2
BeOne Medicines Ltd
ONC
$33.9B
$3.02B 11.36%
11,668,897
-1,632,700
-12% -$450M
INCY icon
3
Incyte
INCY
$25.7B
$2.78B 10.49%
31,999,741
+343
+0% +$29.7K
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.5B
$2.24B 8.44%
41,904,586
– –
KOD icon
5
Kodiak Sciences
KOD
$2.49B
$2.04B 7.68%
13,879,952
+1,527,777
+12% +$170M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$1.37B 5.16%
8,760,794
– –
PRLD icon
7
Prelude Therapeutics
PRLD
$367M
$724M 2.73%
10,118,636
– –
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.9B
$666M 2.51%
7,589,294
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$654M 2.47%
15,649,182
+3,798,220
+32% +$181M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.7B
$590M 2.22%
3,540,270
– –
ABCL icon
11
AbCellera Biologics
ABCL
$1.68B
$421M 1.58%
+10,450,180
New +$478M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$310M 1.17%
1,409,784
– –
ARGX icon
13
argenx
ARGX
$55.1B
$300M 1.13%
1,019,557
– –
IGMS
14
DELISTED
IGM Biosciences
IGMS
$278M 1.05%
3,144,892
+446
+0% +$31.4K
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.5B
$167M 0.63%
1,499,213
– –
AMRN
16
Amarin Corp
AMRN
$302M
$137M 0.52%
1,399,588
-201,355
-13% -$19.4M
HRTX icon
17
Heron Therapeutics
HRTX
$92.6M
$127M 0.48%
5,994,704
– –
KYMR icon
18
Kymera Therapeutics
KYMR
$8.71B
$121M 0.46%
1,959,211
– –
ALLK
19
DELISTED
Allakos
ALLK
$100M 0.38%
714,250
+15,781
+2% +$1.64M
CERS icon
20
Cerus
CERS
$575M
$94.9M 0.36%
13,713,195
– –
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.45B
$94.6M 0.36%
12,695,818
– –
PACB icon
22
Pacific Biosciences
PACB
$438M
$83.1M 0.31%
3,201,972
-48,028
-1% -$816K
ZYME icon
23
Zymeworks
ZYME
$1.62B
$80.7M 0.3%
1,708,472
– –
INSM icon
24
Insmed
INSM
$22.5B
$71.8M 0.27%
2,156,001
-116,711
-5% -$4.26M
FMTX
25
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$70.7M 0.27%
2,024,876
+253,367
+14% +$11M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Baker Bros. Advisors held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Baker Bros. Advisors's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Baker Bros. Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 7 in Q4 2020.
  • Baker Bros. Advisors's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.